Interius BioTherapeutics to Present at Upcoming Scientific Meetings
PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today announced that it will present at several upcoming scientific meetings.
Cellicon Valley '25: The Future of Cell and Gene Therapies
Philadelphia, PA
April 30 – May 2, 2025
- Plenary Session: Are In Vivo Cell Therapies the Key to the Future of Medicine?
- Presentation Title: Cell-specific in vivo gene delivery: A pipeline dream no longer
- Presenter: Philip Johnson, M.D., Chief Executive Officer, Interius BioTherapeutics
- Presentation Date and Time: Thursday, May 1, at 3:50 pm EDT
International Society for Cell and Gene Therapy (ISCT) 2025 Annual Meeting
New Orleans, LA
May 7 – 10, 2025
- Scientific Session: In Vivo Cell Engineering: Breaking Through the Manufacturing Bottleneck
- Presentation Title: INVISE: A first-in-human Phase 1 clinical trial evaluating the safety of INT2104 for in vivo generation of CAR T and CAR NK cells in adults with relapsed/refractory B cell malignancies
- Presenter: Dr. David Bishop, Haematologist, Westmead Hospital, Sydney, Australia
- Presentation Date and Time: Friday, May 9, at 9:15 am CT
American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
New Orleans, LA
May 13 – 17, 2025
- Scientific Symposium: The Coalition of International Gene Therapy Societies Showcases: Moving from ex vivo Cell Therapies to in vivo
- Presentation Title: Investigational in vivo CAR-T therapy designed to treat B-cell malignancies
- Presenter: Philip Johnson, M.D., Chief Executive Officer, Interius BioTherapeutics
- Presentation Date and Time: Thursday, May 15, from 3:45 – 5:30 pm CT
- Location: Room 265-268
About Interius BioTherapeutics
Interius BioTherapeutics is a clinical stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases in oncology, autoimmunity and beyond. Leveraging a proprietary platform, Interius has created a differentiated off-the-shelf therapeutic modality designed for broad patient access. The Company’s lead programs aim to overcome the current limitations of ex vivo chimeric antigen receptor (CAR) T-cell therapy by creating therapeutic CAR cells directly in the patient’s body, avoiding preconditioning chemotherapy, manufacturing bottlenecks, and high costs.
For more information, visit www.interiusbio.com and follow us on LinkedIn.
Media Contact
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
+1 646-386-1613
